Novo Nordisk (NYSE:NVO) announced that it is planning to introduce its weight-loss medication Wegovy in vials.
“We are exploring various device presentations for Wegovy, including vials—some are launching this year, others are coming in the future,” the company said.
Currently, Wegovy is available in both injectable and oral forms.
The move follows rival Eli Lilly, which began offering vials of the two lowest doses of its weight-loss drug Zepbound in 2024. Last year, Lilly reduced prices for Zepbound vials and expanded the range of doses available online.
Zepbound overtook Wegovy in US prescriptions during 2025, marking a challenging period for Novo Nordisk. The company’s plan to introduce vials is seen as part of its effort to regain market share in the competitive obesity-drug sector.
Shares of Novo Nordisk traded down 0.9% on Thursday at about $48, down about 5% so far this year.